Glaucoma costs to double by 2025

Article

A new study shows that costs associated with glaucoma will more than double by 2025.

A new study shows that costs associated with glaucoma will more than double by 2025. The Australian study has estimated costs in the country to reach AUS$4.3 billion (around E2.6 billion) by 2025, more than double the total cost in 2005.

The report, "Tunnel Vision: the Economic Impact of Primary Open Angle Glaucoma", released by the Centre for Eye Research Australia and Access Economics, showed costs associated with glaucoma totalled AUS$1.9 billion in 2005. The report recommends changes to current practice to reduce the projected 2025 costs, including a public health awareness campaign. Of the 300 000 Australians living with glaucoma, half of these are currently unaware that they have the condition; late diagnosis is associated with increased cost of treatment due to extensive disease progression.

The report's recommended measures also include conducting studies to compare laser treatments with traditional glaucoma therapies and research into better understanding the pathophysiology of glaucoma, leading to the development of new, more cost-effective treatments.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.